Artwork

Proactive Investors द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Proactive Investors या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal
Player FM - पॉडकास्ट ऐप
Player FM ऐप के साथ ऑफ़लाइन जाएं!

Lumos Diagnostics extends BDI agreement to address clinical needs

5:14
 
साझा करें
 

Manage episode 436563285 series 2891889
Proactive Investors द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Proactive Investors या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal
Lumos Diagnostics Ltd (ASX:LDX, OTC:LDXHF) chief technology officer Sacha Dopheide joins Proactive’s Tylah Tully to discuss an extended agreement with Burnet Diagnostics Initiative (BDI) to further develop and manufacture a liver function test based on Alanine Transaminase (ALT) levels. The BDI agreement includes the production of ALT lateral flow tests, customised Lumos readers and a mobile application for use in an upcoming US clinical trial. The partnership, which began with a feasibility project in July 2023, aims to address critical clinical needs through rapid point-of-care testing. The new phase of the collaboration is set to begin in August 2024 and will focus on the production of a point-of-care ALT testing system, specifically designed to monitor liver function in high-risk patients. The ALT test is expected to provide rapid results, enabling quicker detection of acute liver toxicity, potentially caused by drug reactions. Lumos will offer development, regulatory and manufacturing services over the next 9-12 months, with projected revenues between US$700,000 and US$1 million. If successful, Lumos may continue to support BDI in further development stages, including additional trials and regulatory submissions. The partnership underlines Lumos’ commitment to advancing point-of-care diagnostics and improving patient outcomes. Partnerships and agreements form a large part of the company’s revenue stream helping it leverage its other client offerings. #Proactiveinvestors #LumosDiagnostics #ASX #HealthcareInnovation, #FDAApproval, #PointOfCare, #MedicalDiagnostics, #WomensHealth, #Hologic, #FebriDx, #ViraDx, #FluSeason, #GlobalHealthcare, #MedicalDevices, #HealthcareSolutions, #RevenueGrowth, #StrategicPartnerships, #Diagnostics, #Biotech, #HealthcareTechnology, #FinancialResults, #MedTech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

608 एपिसोडस

Artwork
iconसाझा करें
 
Manage episode 436563285 series 2891889
Proactive Investors द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Proactive Investors या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal
Lumos Diagnostics Ltd (ASX:LDX, OTC:LDXHF) chief technology officer Sacha Dopheide joins Proactive’s Tylah Tully to discuss an extended agreement with Burnet Diagnostics Initiative (BDI) to further develop and manufacture a liver function test based on Alanine Transaminase (ALT) levels. The BDI agreement includes the production of ALT lateral flow tests, customised Lumos readers and a mobile application for use in an upcoming US clinical trial. The partnership, which began with a feasibility project in July 2023, aims to address critical clinical needs through rapid point-of-care testing. The new phase of the collaboration is set to begin in August 2024 and will focus on the production of a point-of-care ALT testing system, specifically designed to monitor liver function in high-risk patients. The ALT test is expected to provide rapid results, enabling quicker detection of acute liver toxicity, potentially caused by drug reactions. Lumos will offer development, regulatory and manufacturing services over the next 9-12 months, with projected revenues between US$700,000 and US$1 million. If successful, Lumos may continue to support BDI in further development stages, including additional trials and regulatory submissions. The partnership underlines Lumos’ commitment to advancing point-of-care diagnostics and improving patient outcomes. Partnerships and agreements form a large part of the company’s revenue stream helping it leverage its other client offerings. #Proactiveinvestors #LumosDiagnostics #ASX #HealthcareInnovation, #FDAApproval, #PointOfCare, #MedicalDiagnostics, #WomensHealth, #Hologic, #FebriDx, #ViraDx, #FluSeason, #GlobalHealthcare, #MedicalDevices, #HealthcareSolutions, #RevenueGrowth, #StrategicPartnerships, #Diagnostics, #Biotech, #HealthcareTechnology, #FinancialResults, #MedTech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

608 एपिसोडस

Alla avsnitt

×
 
Loading …

प्लेयर एफएम में आपका स्वागत है!

प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।

 

त्वरित संदर्भ मार्गदर्शिका